◆ What the Market Isn't Pricing In

Intuitive Surgical (ISRG) — the variant view

The moat is intact, the growth rate is lower, and the company has just chosen to trade toll for volume — which nobody is modelling.

📈 ISRG valuation, revenue & earnings — P/E, P/S, revenue, EPS →

Intuitive has spent five consecutive years at between 66 and 80 times earnings. It is now at about 451. That is the whole argument, and both sides of it are stronger than the discussion suggests.

Trailing price/earnings80x202166x202280x202370x202466x202541xSept 2026Five consecutive years between 66 and 80 times earnings, then 41.
Recurring revenue rose to 85%, utilisation rose 3%, gross margin rose to 67.8% and operating income grew 31%. The de-rating is not about the machine.

The bull case is that nothing structural has broken. Recurring revenue was 84% of the total in 2025 and 85% in the June 2026 quarter2. The installed base grew 12% to 11,710 da Vinci systems and utilisation rose 3% on top of it3 — the fleet is both larger and busier. Gross margin went up, not down: 66.0% for 20254 and 67.8% in the June quarter, with full-year non-GAAP guidance raised to 68-69%5. Operating income grew 31% in the quarter. The balance sheet holds $8.63 billion and no debt. On any measure of the machine, this was a good year.

The bear case is that the machine was never the constraint. More than half of da Vinci procedures are for benign conditions6, and the demand for benign procedures turns out to be a function of American health insurance. That is not a cyclical discovery; it is a permanent feature that had simply never been tested, because coverage had been expanding for a decade.

Three things are being under-weighted in between.

The first is that Intuitive has begun cutting its own toll, and it is the most informative thing the company did in 2026. The Extended Use Program will raise the permitted number of uses on selected EndoWrist instruments in the first half of 2027 to reduce costs in benign procedures7. The chip that counts down is the enforcement mechanism of the entire razor-and-blade model8, and the company is voluntarily loosening it to defend volume. Asked whether mix could hold instrument revenue per procedure flat through the change, the chief financial officer would not commit9. That is a real, self-inflicted, disclosed margin headwind arriving in 2027, and it is not in most models.

The second is that the twenty-five-year monopoly ended while nobody was looking at it. Medtronic's Hugo was cleared for urology on 3 December 2025 and Johnson & Johnson's Ottava received De Novo authorisation on 22 July 202610. Neither will take share quickly. Both permanently change what a hospital can say in a negotiation, and Intuitive's average selling price — $1.60 million, still rising11 — has never had to survive that conversation.

The third runs the other way and is the most ignored. The international business is compounding at nearly twice the domestic rate — OUS procedures +23% in 202512 and +20% in the June quarter against 12% domestically13 — with a healthier procedure mix and a reimbursement environment that is currently improving rather than deteriorating. Japan expanded coverage on 1 June 2026 and placements there went from 15 to 25 in a quarter14. A company whose American growth is capped by insurance policy and whose international growth is not is a different company in five years than it is today.

Put together: the moat is genuinely wide and genuinely intact, the growth rate is genuinely lower, and the multiple has moved from pricing the first to pricing the second. What almost nobody is pricing is that Intuitive is now willing to trade toll for volume — which is the correct decision, and which means the recurring revenue per procedure that everyone models as a constant is a variable that management controls and has just chosen to reduce.

References
  1. ReportedIt is now at about 45.
    Intuitive Surgical (NASDAQ: ISRG) market data, 23 September 2026 - $398.58 a share, market capitalisation $140.81 billion on 353.28 million shares, P/E 46.11, forward P/E 35.59; 52-week high $603.88 (companiesmarketcap: $142.84 billion) — September 2026 · publ. 2026-09-23 · source ↗
  2. ReportedRecurring revenue was 84% of the total in 2025 and 85% in the June 2026 quarter.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  3. ReportedThe installed base grew 12% to 11,710 da Vinci systems and utilisation rose 3% on top of it — the fleet is both larger and busier.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  4. ReportedGross margin went up, not down: 66.0% for 2025 and 67.8% in the June quarter, with full-year non-GAAP guidance raised to 68-69%.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
  5. ReportedGross margin went up, not down: 66.0% for 2025 and 67.8% in the June quarter, with full-year non-GAAP guidance raised to 68-69%.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  6. ReportedMore than half of da Vinci procedures are for benign conditions, and the demand for benign procedures turns out to be a function of American health insurance.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  7. ReportedThe Extended Use Program will raise the permitted number of uses on selected EndoWrist instruments in the first half of 2027 to reduce costs in benign procedures.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  8. ReportedThe chip that counts down is the enforcement mechanism of the entire razor-and-blade model, and the company is voluntarily loosening it to defend volume.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  9. ReportedAsked whether mix could hold instrument revenue per procedure flat through the change, the chief financial officer would not commit.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  10. ReportedMedtronic's Hugo was cleared for urology on 3 December 2025 and Johnson & Johnson's Ottava received De Novo authorisation on 22 July 2026.
    MedTech Dive, 'Medtronic's Hugo surgical robot earns FDA clearance' - Hugo cleared in the United States for urologic procedures in December 2025, the first large-company alternative to da Vinci in the largest robotic surgery market, with general surgery and gynecology still to come — December 2025 · publ. December 4, 2025 · source ↗
  11. ReportedBoth permanently change what a hospital can say in a negotiation, and Intuitive's average selling price — $1.60 million, still rising — has never had to survive that conversation.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  12. ReportedThe international business is compounding at nearly twice the domestic rate — OUS procedures +23% in 2025 and +20% in the June quarter against 12% domestically — with a healthier procedure mix and a reimbursement environment that is...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
  13. ReportedThe international business is compounding at nearly twice the domestic rate — OUS procedures +23% in 2025 and +20% in the June quarter against 12% domestically — with a healthier procedure mix and a reimbursement environment that is...
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  14. ReportedJapan expanded coverage on 1 June 2026 and placements there went from 15 to 25 in a quarter.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
Sources
Generated September 23, 2026